Key Primary Resverlogix Objective Obtained



    TSX Exchange Symbol: RVX

    Findings demonstrate clear trends of proof of principle of reverse
    cholesterol transport in human volunteers

    SAN DIEGO, CA and CALGARY, June 18 /CNW/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) announced today that it has
completed the planned exploratory efficacy analysis of the data from the
Phase I, 7 day RVX-208 treatment subjects. Analysis from two independent and
external laboratories of blinded serum samples showed consistent improvements
of key biomarkers for the RCT (reverse cholesterol transport) pathway.
    "Analysis from 24 healthy volunteers in the 7 day RVX-208 trial showed
statistically significant improvements over placebo in 3 of the 4 key
variables assessed," stated Donald J. McCaffrey, President & CEO of
Resverlogix. A fourth variable also showed positive trending but was not
validated as statistically significant. McCaffrey emphasized, "All other lipid
parameters behaved as anticipated. As efficacy is the one of the goals of our
upcoming 28 day Phase 1b/2a trial we are very pleased to see the primary
indicators behaving as they did. We were especially pleased to see the
increases in pre-beta HDL of in excess of 30%, cholesterol efflux above 10%,
serum ApoA-l above 10%, and HDL-C above 10% (not statistically significant)
versus placebo. This follows a very similar improvement pattern as previously
demonstrated by Resverlogix in the African Green Monkey studies. Crucial to
these findings is the rapid onset of action in this 7 day trial, with the
serum ApoA-I increases surpassing the previous 8% five week (35 day) average
benchmark totals displayed by Pfizer's previous ApoA-I Milano recombinant
protein studies."
    McCaffrey continued, "What has been truly unique about RVX-208 versus
other small molecule HDL/ApoA-I programs is that RVX-208 facilitates
endogenous ApoA-I production. Resverlogix now has a commanding lead in the
development of atherosclerosis therapeutics. To our knowledge no other small
molecules, whether it is the statins, other HDL drugs or lipid modifying
programs have demonstrated HDL functionality and RCT."
    RCT is a pathway by which accumulated cholesterol is transported from the
arterial wall to the liver for excretion, thus preventing atherosclerosis.
Major constituents of RCT include acceptors such as high-density lipoprotein
(HDL) and apolipoprotein A-I (ApoA-I). A critical part of RCT is cholesterol
efflux, in which accumulated cholesterol is removed from macrophages.
    Resverlogix will be presenting at the BIO Business Forum held in San
Diego, California on Thursday June 19, 2008 at 1:15pm PDT in Room 4.

    About Resverlogix Corp.

    Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's and other
vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as cancer and
fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.

    This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.

    %SEDAR: 00019253E




For further information:

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Sarah@resverlogix.com, Website: www.resverlogix.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890